Company profile: GreenLight Biosciences
1.1 - Company Overview
Company description
- Provider of RNA-based solutions for agriculture and human health, offering a proprietary platform to produce RNA at scale cost-effectively and products targeting pests and diseases without harming beneficial insects, including Varroa mite control for honeybees and Calantha, an EPA-approved RNA product for Colorado Potato Beetle control.
Products and services
- RNA Production Platform: Produces RNA at industrial-scale for agricultural and human health applications, delivering cost-effective, high-quality RNA products for both sectors
- Calantha: EPA-approved RNA-based product for controlling Colorado Potato Beetles in potato crops, designed to be environmentally friendly and to leave no harmful residues
- RNA-Based Agricultural Products: Biologically targeted RNA crop protection systems that target specific pests and diseases, enhancing crop protection while avoiding harm to beneficial insects
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to GreenLight Biosciences
Cergentis
HQ: The Netherlands
Website
- Description: Provider of services and kits based on proprietary Targeted Locus Amplification (TLA) technology, enabling cost-effective complete sequencing of relevant genes and genomic loci and providing genetic characterization and quality control (QC) to support the development of advanced, safe and effective therapies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Cergentis company profile →
Airna
HQ: United States
Website
- Description: Provider of RNA editing technologies and therapeutics, including the RESTORE+ RNA editing platform to optimize sequence, chemistry, and delivery for precise RNA editing to treat rare and common diseases. Offers RNA editing therapeutics for alpha-1 antitrypsin deficiency (AATD) and a pipeline addressing diseases with high unmet need.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Airna company profile →
HeartGenetics
HQ: Portugal
Website
- Description: Provider of DNA microchip-based genotyping technology for cardiac genetic diseases, enabling high-throughput and high-accuracy genetic analysis on a DNA Microchip platform optimized with an iPlex MassArray system.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full HeartGenetics company profile →
Gentris
HQ: United States
Website
- Description: Provider of global pharmacogenomic testing and biorepository services, helping pharmaceutical companies and clinical research organizations integrate pharmacogenomics into drug development to deliver safer, more effective compounds to market more quickly.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Gentris company profile →
Diagnomics
HQ: United States
Website
- Description: Provider of NGS-based genomics solutions for personalized medicine and next-generation healthcare, offering high-quality R&D and CLIA services including whole genome, exome and RNA sequencing, microarray services, bioinformatics analysis, and clinical/translational research support.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Diagnomics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for GreenLight Biosciences
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to GreenLight Biosciences
2.2 - Growth funds investing in similar companies to GreenLight Biosciences
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for GreenLight Biosciences
4.2 - Public trading comparable groups for GreenLight Biosciences
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →